357 related articles for article (PubMed ID: 26333950)
1. Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations.
Jeong IH; Kim SH; Hyun JW; Joung A; Cho HJ; Kim HJ
J Neurol Sci; 2015 Nov; 358(1-2):118-24. PubMed ID: 26333950
[TBL] [Abstract][Full Text] [Related]
2. Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations.
Li X; Miao X; Wang Y; Sun J; Gao H; Han J; Li Y; Wang Q; Sun C; Liu J
Front Immunol; 2022; 13():1052678. PubMed ID: 36532021
[TBL] [Abstract][Full Text] [Related]
3. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
[TBL] [Abstract][Full Text] [Related]
4. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
Totaro R; Di Carmine C; Splendiani A; Torlone S; Patriarca L; Carrocci C; Sciamanna S; Marini C; Carolei A
Neurol Sci; 2016 Jul; 37(7):1113-7. PubMed ID: 27083895
[TBL] [Abstract][Full Text] [Related]
5. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system inflammatory demyelinating disorders among Hong Kong Chinese.
Chan KH; Lee R; Lee JC; Tse AC; Pang SY; Lau GK; Teo KC; Ho PW
J Neuroimmunol; 2013 Sep; 262(1-2):100-5. PubMed ID: 23838529
[TBL] [Abstract][Full Text] [Related]
7. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.
Karussis D
J Autoimmun; 2014; 48-49():134-42. PubMed ID: 24524923
[TBL] [Abstract][Full Text] [Related]
8. The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project.
Papais-Alvarenga RM; Vasconcelos CC; Alves-Leon SV; Batista E; Santos CM; Camargo SM; Godoy M; Lacativa MC; Lorenti M; Damasceno B; Damasceno A; Brum D; Barreira AA; Guimarães Rocha MS; Alvarenga H; Tilbery CP
Mult Scler; 2014 Mar; 20(3):374-81. PubMed ID: 23970504
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
Huh SY; Min JH; Kim W; Kim SH; Kim HJ; Kim BJ; Kim BJ; Lee KH
Mult Scler; 2014 May; 20(6):695-704. PubMed ID: 24072726
[TBL] [Abstract][Full Text] [Related]
10. Seizures in inflammatory demyelinating disorders of the central nervous system.
Ertürk Çetin Ö; Güngör Doğan İ; Zanapalioğlu Ü; Yadi F; Çetinkaya Tezer D; Demir S
Mult Scler Relat Disord; 2024 May; 85():105535. PubMed ID: 38452647
[TBL] [Abstract][Full Text] [Related]
11. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
[TBL] [Abstract][Full Text] [Related]
12. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
[TBL] [Abstract][Full Text] [Related]
13. Nationwide Incidence of Acquired Central Nervous System Demyelination in Icelandic Children.
Gudbjornsson BT; Haraldsson Á; Einarsdóttir H; Thorarensen Ó
Pediatr Neurol; 2015 Dec; 53(6):503-7. PubMed ID: 26463471
[TBL] [Abstract][Full Text] [Related]
14. Silent Tumefactive Demyelinating Lesions and Radiologically Isolated Syndrome.
Ekmekci O; Eraslan C
Case Rep Neurol Med; 2018; 2018():8409247. PubMed ID: 30622825
[TBL] [Abstract][Full Text] [Related]
15. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.
Sánchez P; Meca-Lallana V; Barbosa A; Manzanares R; Palmí I; Vivancos J
J Neurol Sci; 2017 Oct; 381():32-38. PubMed ID: 28991707
[TBL] [Abstract][Full Text] [Related]
16. Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions.
Ayrignac X; Rigau V; Lhermitte B; Vincent T; de Champfleur NM; Carra-Dalliere C; Charif M; Collongues N; de Seze J; Hebbadj S; Ahle G; Oesterlé H; Cotton F; Durand-Dubief F; Marignier R; Vukusic S; Taithe F; Cohen M; Guennoc AM; Kerbrat A; Edan G; Carsin-Nicol B; Allou T; Sablot D; Thouvenot E; Ruet A; Magy L; Boncoeur-Martel MP; Labauge P; Kremer S
J Neurol; 2019 Jul; 266(7):1743-1755. PubMed ID: 31016376
[TBL] [Abstract][Full Text] [Related]
17. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease.
Siva A; Saip S; Altintas A; Jacob A; Keegan BM; Kantarci OH
Mult Scler; 2009 Aug; 15(8):918-27. PubMed ID: 19667020
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of aquaporin-4 antibody in patients of inflammatory demyelinating diseases in central nervous system].
Yang Y; Wu WP; Huang DH; Wu L
Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(43):3032-5. PubMed ID: 23328372
[TBL] [Abstract][Full Text] [Related]
19. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder.
Kim W; Kim SH; Lee SH; Li XF; Kim HJ
Mult Scler; 2011 Sep; 17(9):1107-12. PubMed ID: 21543554
[TBL] [Abstract][Full Text] [Related]
20. Histogram analysis of apparent diffusion coefficient maps for differentiating primary CNS lymphomas from tumefactive demyelinating lesions.
Lu SS; Kim SJ; Kim N; Kim HS; Choi CG; Lim YM
AJR Am J Roentgenol; 2015 Apr; 204(4):827-34. PubMed ID: 25794073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
